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Table 1
Demographic, laboratory and clinical characteristics of all patients at
baseline
N patients/HCV genotype 1b (%) 16/16 (100%)
Male (%) 12 (75%)
Age (median years, range) 47 (25–64)
Duration of haemodialysis (median years,
range)
14.5 (1–28)
HCV RNA (median IU/mL, IQRa) 18350 (910–469,000)
Outcome of antiviral therapy
(SVR/NR/Ra)
11 (68.8%)/3 (18.8%)/2
(12.5%)
Previous renal transplant (N, %) 13 (81.3%)
Retained graft in situ (N, %; median
months, range)
6 (37.5%); 14 (4–240)
a Abbreviations: IQR, interquartile range; SVR, sustained virologic
response; NR, non-responder; R, relapse.
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ity and ﬁbrosis. Antiviral therapy was begun in June
2006. Despite the withdrawal of ribavirin at week 4
due to anaemia, the patient attained SVR. However,
ten weeks after the onset of therapy, he experienced
chills, fever and a painful graft. Antiviral treatment
was stopped at week 14 and the patient underwent graf-
tectomy. Compatible with the acute-on-chronic allograft
rejection, the histology showed almost complete haem-
orrhagic necrosis of the graft.
In line with previous case records [3,4] and a recent
cohort study [5], and contrary to the study of Rendina
et al. [2], we conclude that even haemodialysed patients
with non-functional renal allograft retained in situ may
experience acute allograft rejection following peginter-
feron-a2a treatment of hepatitis C. Before the start of
antiviral therapy, these patients may need to be advised
of this eventuality and should be aware of the possible
need for graftectomy. In patients who present with graft
failure less than one year prior to treatment withpeginterferon-a and who seem to be most prone to acute
rejection, it may seem reasonable to endorse preemptive
graftectomy.
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with peginterferon alpha-2a: Reply2To the Editor:
We have read very carefully the Letter to the Editor
by Dr. Sperl and collegues and the answers to the ques-
tions they raised are provided below:
1. In our series, of the 19 haemodialysed patients, who had
previously been transplanted, 14 had retained the graft
in situ. Five patients, before treatment, had already been
submitted to graftectomy on account of symptoms such
as, for example, acute rejection which occurred after a
mean time of 3–7 months after graft failure. As far asconcerns immunosuppressive treatment, the policy in
our centre is to stop Calcineurin inhibitors and to taper
steroids within 3 months of graft failure. Our patients
received anti-viral treatment only after a mean period
of 12–36 months after graft failure.
. In the series described by Dr. Sperl, interferon treat-
ment was started very early after graft loss (i.e., 4 and
8 months) and no information is provided regarding
either immunosuppressive treatment or the immuno-
logical background of the two patients. We chose to
start treatment after a period of clinical and immuno-
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sis) on the basis of previous experience showing that
most cases of rejection occurred before this time
interval.
With regard to the rate of side-eﬀects, thismay be due to
the fact that a high dose of interferon was used by the
authors, while ribavirin was avoided in most cases. Con-
versely, and as reported in our paper, we carefully assessed
the type and dosage of pegylated interferon (i.e., peginter-
feron alpha-2a, 135 lg/weekly) due to the presence of
chronic renal failure and individually tailored the dosage
of ribavirin to avoid even more severe anaemia which
was controlled by administration of erythropoietin. This
strategy resulted in a strong anti-viral eﬀect and avoided,
in most instances, major side-eﬀects and, probably, also
rejection.
To better deﬁne the use of graftectomy, further stud-
ies, on a larger series, are necessary focusing on compar-
isons between the rejection rates in patients receiving
interferon and those not receiving interferon. On the
basis of our experience and available data, anti-viraltreatment should, in our opinion, be delayed until 12
months after graft loss.
We wish to thank Dr. Sperl who gave us the
opportunity to emphasize these points which complete
our results and would, no doubt, contribute to
improving the pharmacological approach with pegylat-
ed interferon and ribavirin in this particular category
of patients.
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doi:10.1016/j.jhep.2008.06.001Neonatal classical galactosaemia presenting as citrin deﬁciencyTo the Editor:
Wereadwith interest the recent study byFeillet et al. [1].
This is an elegant paper which eloquently analyses and ex-
plains what turned out to be a secondarymetabolic abnor-
mality. We agree that neonatal citrin deﬁciency needed to
be considered as a diﬀerential diagnosis, albeit a rare one.
Clinical presentation of citrin deﬁciency is heterogeneous
andnon speciﬁc andgalactosaemia is awell recognisedbio-
chemical feature. Although citrullinaemia is common it is
not speciﬁc, may be absent and the diagnosis of citrin deﬁ-
ciency today largely depends on mutation analysis.
In neonatal liver failure, in particular, it is often diﬃcult
to distinguish between what are primary metabolic abnor-
malities causing liver dysfunction and secondary abnor-
malities as a result of liver dysfunction. The situation can
becomeparticularly complicatedwhen there has been a de-
lay in diagnosis or partial treatment as in this case.
In the setting of such a complexmulti-systemic disease,
it is important to have some simple guiding principles.
Galactosaemia is one of the commonest causes of neona-
tal liver failure. A galactose free diet should be given to all
children with neonatal liver failure until galactosaemia
has been speciﬁcally excluded by enzyme analysis. Agalactose challenge is neither appropriate nor necessary
as a diagnostic test for galactosaemia and is not without
risk.Anapproach to the diagnosis or exclusion of possible
galactosaemia when the situation is complicated is sum-
marised in a recent review [2].
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